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Abstract
We report the case of a male patient from an Ashkenazi Jewish ethnic group with a history of midline defects 
(congenital heart disease, high-arched palate and bifid uvula). At the age of 46 years, he came to our center 
complaining of resting tremor, and a neurological examination concluded Parkinson’s disease. As a part of his 
approach, genetic evaluation was performed. Fluorescence in-situ hybridization (FISH) confirmed a mosaicism of 
a 22q deletion in 24% of the analyzed blood cells. Also, immunohistochemical studies were performed on samples 
from the minor salivary glands using a SNCA antibody. Intense SNCA immunoreactive profiles were obtained for 
cells from the salivary glands of the patient. This is, to our knowledge, the first description of the association of a 
mosaicism of a 22q11.2 microdeletion syndrome with Parkinson’s disease. 
Our findings suggest that, before excluding the involvement of the 22q11.2 deletion in the etiology of early-
onset PD cases, the spectrum of evaluations should be extended to include more sensitive FISH analysis and 
immunohistochemical studies. The pathogenesis of early-onset PD in patients with 22q11.2 deletion syndrome 
remains unknown but, if elucidated, it may contribute to understanding the etiology of PD and ultimately to prevention 
and treatment strategies.
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Introduction
The 22q11.2 deletion syndrome (22qDS), also known as Di George 
Syndrome or Velocardiofacial Syndrome (VCFS), is a common genetic 
disorder. It results from an autosomal dominant microdeletion on the 
long (q) arm of chromosome 22 which occurs de novo in approximately 
90% of cases and is inherited in approximately 5–10% [1].
Prevalence of 22qDS is approximately 1 in 4000 live births [2]. The 
phenotypic presentation of VCFS is extensive and shows substantial 
variability across individuals [3]. The hallmark features of the syndrome 
are characteristic facial appearance, velopharyngeal insufficiency, 
conotruncal heart disease, parathyroid and immune dysfunction, 
developmental delays and learning difficulties [4].
Early-onset Parkinson disease (PD) refers to patients presenting 
with onset before the 50 years [5]. In this group, the probability of an 
inherited form is increased. Known genetic mutations account for 4% 
to 16% of early-onset PD cases [6,7] including LRRK2, PARK2, SNCA, 
PARK7, and PINK1 [8].
Case Report
We report the case of a 46-year-old male patient from an Ashkenazi 
Jewish ethnic group. He had a history of preterm birth at 7 months 
because of premature rupture of membranes. He was diagnosed with 
congenital heart disease (interventricular communication and subaortic 
stenosis) which was corrected surgically; he was also diagnosed with 
congenital left deafness and right hearing loss, high-arched palate and 
bifid uvula.
In his medical family history, his maternal grandfather had been 
evaluated because of psychiatric symptoms without a definitive 
diagnosis. His great-uncle in his maternal line was diagnosed with 
Parkinson’s disease at the age of 70, while his second cousin in his 
maternal line suffered from mental retardation and congenital deafness. 
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Regarding his past medical history, he experienced seizures at 
6 years in the context of fever. At the age of 10, he presented gum 
bleeding and after hematological evaluation he was diagnosed with Von 
Willebrand disease. 
Because of psychomotor retardation, his academic performance 
was poor; he attended a special school. During adulthood, he was 
diagnosed with hepatitis C related to transfusions performed for cardiac 
surgery (subaortic stenosis); he was treated with pegylated interferon 
and ribavirin. He had no history of antipsychotic medication use or 
other dopamine blockers. 
At the age of 46, he was brought by her mother complaining of left 
arm tremor, which presented mainly at rest. Because of his cognitive 
deficits and movement disorder, a previous physician had considered a 
diagnosis of Wilson’s disease. In anamnesis, he denied the presence of 
pre-motor signs; a subsequent otolaryngological evaluation, however, 
revealed severe olfactory alteration in an olfactometry tests.
A general physical examination showed the presence of hypernasal 
speech, short stature and bifid uvula.
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On neurological examination, the patient was found inattentive. 
In cranial nerves, ocular motility was preserved, there was left eighth 
nerve deafness and hypoacusia in the right; motor examination showed 
hypophonia and hypomimia, marked bradikinesia in both arms, 
bilateral cogwheel rigidity and resting tremor in his upper extremities, 
predominating in the left arm. He also had postural and intention 
tremor, predominating in the left arm. We concluded PD and calculated 
UPDRS at that moment was 40 points. Additional investigations 
included ophthalmologic examination, which was negative for Kayser-
Fleischer ring, and otolaryngological evaluation, which showed severe 
alteration on olfactometry.
He was started on ropinirole with modest clinical motor response, 
and a subsequent challenge with levodopa turned out positive, so 
we progressively titrated up the dose. While being on this dopamine 
agonist, he developed behaviors such as ordering objects, closing doors 
and cleaning the floor, compatible with punding, which were not 
problematic. He also developed insomnia, irritability, emotional lability, 
fear of being alone and disorganized conduct; therefore, quetiapine and 
clonazepam were added. During the following weeks, it was necessary 
to add levodopa and as the compulsive behavior worsened, ropinirole 
was tapered slowly without improvement. The department of psychiatry 
considered it necessary to add carbamazepine and promethazine, 
but the latter worsened the parkinsonian symptoms. Promethazine 
was then discontinued, with improvement of the motor aspect. Later 
levodopa was titrated up, with good clinical motor response.
Results
Blood count
(January 2012) Hemoglobin 14.7, mean corpuscular volume 85, 
hematocrit 44.0, erythrocytes 5.17, leukocytes 5.0, lymphocytes 40%, 
monocytes 10%, neutrophils 44%, eosinophils 5%, platelets 203 000.
Hemostatic evaluation
(December 2014): aPTT 37 sec., factor VIII 110%, Ristocetin 
cofactor 170%, Von Willebrand Factor 110%.
Platelet function
(December 2014): Bleeding time 5.0 minutes, in vivo platelet 
adhesiveness 30%.
(January 2012) Liver function tests: Alkaline phosphatase 63, total 
bilirubin 0.7 mg/dl, indirect bilirubin 0.4 mg/dl, direct bilirubin 0.3 
mg/dl, aspartate aminotransferase 25 U/l, alanine aminotransferase 21 
U/l, gamma-glutamyl transpeptidase 25 U/l, total proteins 7.4 g/dl. 
(January 2012) Ceruloplasmin: 42 mg/dl. Urine copper: 24 ug/24 h. 
(January 2012) Electrophoretic proteinogram: Total protein 7.4 g/
dl, albumin 4.0 g/dl, alpha 1 globulin 0.28 g/dl, alpha 2 globulin 0.63 g/
dl, beta globulin 0.86 g/dl, gamma globulin 1.63 g/dl.
(January 2012) Ionogram: Na 139 mEq, K 4.0 mEq, urea 43 mg/dl, 
creatinine 0.7 mg/dl. TSH 1.45, Total T3 1.28, Total T4 7.6.
Imaging studies 
Brain MRI showed cortical atrophy. There was no evidence of metal 
deposits. Heart Doppler: Mild to moderate aortic insufficiency, normal 
left ventricular function, subaortic septal hypertrophy.
Genetic studies
FISH analysis: FISH (Fluorescent In-Situ Hybridization) was 
conducted using probes that had been labeled with fluorescent 
oligonucleotides by means of nick translation. BACs corresponding 
to the control telomeric region -RP11-976a21 were label with FITC 
or the RP5-882j5 deleted region 22q11.2 and RP5-925j7 labeled with 
rhodamine). FISH analysis confirmed a 22q deletion in 24% of the 
evaluated blood cells (Figure 1).
Immunohistochemistry of salivary glands
Immunohistochemical studies were performed on samples from 
the minor salivary glands using the rabbit anti-alpha synuclein antibody 
() and developed with secondary antibody (sc-7011-r #-synuclein 
(C-20)-R and 30 sc-2004 and g anti-rabbit IgG-HRP, Santa Cruz, 
Intl., Ca. USA). Intense SNCA immunoreactive profiles were obtained 
(Figure 2).
Discussion
Although 22qDS is acknowledged as the most common autosomal 
deletion syndrome, the reported prevalence is lower than could be 
expected (1 in 4000 live births) [2]. This may reflect the lack of clinical 
detection in individuals with mild symptoms and/or incomplete 
penetrance. 
The presence of PD in this syndrome has been recently reported. 
This underreporting may be due to confusion with parkinsonian 
symptoms associated with antipsychotic medication prescribed for the 
common psychiatric/behavioral features of the 22q11.2 deletion. This 
was the case of Krahn et al.; they reported parkinsonian symptoms 
for the first time in a patient with schizophrenia and chromosome 22 
microdeletion. However, the use of antipsychotic medication predated 
the development of the parkinsonism [9].
It was Zaleski et al. who showed a consistent association of 
22q11.2 deletion syndrome and PD in two patients. In these cases, 
the association was clear because antipsychotic medication did not 
complicate the diagnosis [10]. 
Possible evidence linking velocardiofacial syndrome with a 
synucleinopathy comes from a previous study, where the authors 
confirmed that substantially more children with 22q11 deletion 
syndrome (68%) as compared with neurotypical control subjects 
(13%) had University of Pennsylvania Smell Identification Test scores 
Figure 1: FISH analysis for 22q deletion syndrome. FISH analysis was 
performed on interphase chromosomes using the following probes: The figure 
shows the overlapping of the fluorescent marks on the DAPI-labeled DNA 
(blue). The loss of one of the red signals indicates the microdeletion. The green 
mark shows the centromere of chromosome 22. The bottom left interphase 
shows a normal nucleus and a metaphase with the microdeletion in one of its 
chromosomes 22 [17].
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≥2 SDs below the standardization sample mean. This study lacked 
histopathological evidence; olfactory dysfunction, however, is typical 
in synucleinopathies [11].
More recently, the largest cohort of adults with a 22q11.2DS 
diagnosis was studied. Individuals with this deletion had a significantly 
elevated occurrence of PD compared with standard population 
estimates (standardized morbidity ratio = 69.7; 95% CI, 19.0-178.5), 
which suggests that 22q11.2 deletions represent a novel genetic risk 
factor for early-onset PD. In this study, the post-mortem analysis 
of 3 patients with 22q11.2 syndrome associated with PD revealed 
dopaminergic neuron loss in the midbrain substantia nigra in all three 
cases. Typical α-synuclein–positive Lewy bodies were present in the 
expected distribution in 2 cases but absent in the other one [12].
In our patient, we could also detect the presence of α-synuclein 
immunoreactive aggregates in his salivary glands, which have been 
shown to accumulate in PD patients and provide further evidence of 
the neurodegenerative pathology in this genetic syndrome [13].
Possible genes implicated in the pathway of PD and 22q11.2 
syndrome include genes contained in the 22q11.2 deletion region, 
among them one of the best known for its role in dopamine catabolism, 
the catechol-O-methyl transferase (COMT) gene [12]. 
Other candidate genes include DGCR8, which encodes a key 
protein involved in the biogenesis of brain micro-RNA [14], micro-
RNA miR-185, predicted to target LRRK2 [15], and SEPT5, which 
encodes a protein that interacts with the product of PARK2 [16]. 
In contrast to previous reports, our patient had a family history of 
Parkinson’s disease. However, it was a second-grade family member, 
and the onset of the disease was in adulthood. 
As there was no previous use of antipsychotics, the diagnosis 
of Parkinson’s disease could be made earlier. In cases where this has 
happened, the diagnosis has been delayed. 
It is important to note that our patient presented symptoms 
consistent with punding; however, they did not resolve when the 
dopamine agonist was discontinued, and he still keeps closing doors 
and ordering objects in our center. Perhaps the psychiatric comorbidity 
common in this disorder constitutes a risk factor for the persistence of 
this behavior, or it was just that psychiatric issues were unmasked by 
dopamine agonists. 
For research purposes, genetic analysis of 22q11.2 should be 
conducted in patients with early-onset PD, or at least in individuals 
with phenotypic features of this syndrome such as cardiac and palatal 
defects, learning difficulties and immunodeficiency, among others. To 
our present knowledge, this is the first description of the association 
of Parkinson’s disease with a mosaicism of a 22q11.2 microdeletion 
syndrome. 
Therefore, this case does not only provide more evidence about 
the relationship between Parkinson’s disease and the 22q11.2 deletion 
syndrome, but it also highlights the relevance of performing individual 
cell-by-cell tests like FISH analysis, at least until single-cell sequencing 
becomes optimized and generally available. The pathogenesis of early-
onset PD in patients with 22qDS remains unknown but, if elucidated, it 
may contribute to understanding the etiology of PD and ultimately to 
prevention and treatment strategies.
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